



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	09/994,227
	Filing Date	November 26, 2001
	First Named Inventor	Alan M. Fogelman
	Group Art Unit	1635
	Examiner Name	Unassigned
	Attorney Docket Number	407T-899210US
Date Submitted	December 9, 2003	


U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
<i>AK</i>	01	6,265,147	B1	Mobley et al.	07-2001	
<i>AK</i>	02	6,299,858	B1	Serbedzija et al.	10-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T	

Examiner Signature		Date Considered	2/24/04
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Modified) PTO/SB/08A-B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Complete if Known	
	Application Number	09/994,227
	Filing Date	November 26, 2001
	First Named Inventor	Alan M. Fog Iman
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	407T-899210US
Date Submitted	January 2, 2003	

RECEIVED


JAN 07 2003

TECH CENTER 1600/2900

14	Dooley ET AL. (1994) "An All D-Amino Acid Opioid Peptide with Central Analgesic Activity from a Combinatorial Library" <i>Science</i> 2019-2022..
15	Fricker ET AL. (1995) "Enteral Absorption of Octreotide: Modulation of Intestinal Permeability by Distinct Carbohydrates" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 274:826-832
16	Fuessl ET AL. (1987) "Oral Absorption of the Somatostatin Analogue SMS 201-995: Theoretical and Practical Implications" <i>Clinical Science</i> 72: 255-257.
17	Greten et al., (1980) <i>Atherosclerosis</i> , 36:81-88
18	Gurfinkel ET AL. (2002) "Influenza Vaccine Pilot Study in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions. The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study" <i>Circulation</i> 105:2143-2147.
19	Hamase ET AL. (2001) "Determination of Free D-Proline and D-Leucine in the Brains of Mutant Mice Lacking D-Amino Acid Oxidase Activity" <i>Analytical Biochemistry</i> 298:253-258.
20	Hardy ET AL. (2001) "An Automated High-Performance Liquid Chromatography Procedure for the Quantitation of L- and D-Amino Acids by Means of Stepwise Precolumn Derivatization" <i>Analytical Biochemistry</i> 291:297-299.
21	Hauser ET AL. (1998) "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine" <i>Biochemistry</i> 178423-17850.
22	Huang et al., (1999) <i>Arterioscler Thromb Vasc Biol.</i> , 1600-1067
23	Huang et al., (2000) <i>Arterioscler Thromb Vase Biol.</i> , 20:210-216
24	Hyka ET AL. (2001) "Apolipoprotein A-I Inhibits the Production of Interleukin-1 $\alpha$ and Tumor Necrosis Factor- $\alpha$ by Blocking Contact-Mediated Activation of Monocytes by T Lymphocytes" <i>Blood</i> 97:2381-2389.
25	Jimenez et al., (1990) <i>J. Nutrition</i> , 120:659-667
26	Jones ET AL. (1992) "Computer Programs to Identify and Classify Amphipathic $\alpha$ Helical Domains" <i>Journal of Lipid Research</i> 33:287-296.
27	Kesaniemi et al., (1986) <i>Amer. J. Clin. Nutr.</i> , 43:98-107
28	Knuiman et al., (1989) <i>Amer. J. Clin. Nutr.</i> , 49:266-268
29	Kullman ET AL. (1999) "Evaluation of the Enantiomeric Composition of Amino Acids in Tobacco" <i>Chirality</i> 11:669-673.
30	Lechowski et al., (1999) <i>Veterinary Research Comm.</i> , 23:1-14
31	Liao et al., (1991) <i>J. Clin. Invest.</i> , 87:6:2256

Examiner Signature	<i>W. Schmidt</i>	Date Considered	3/14/03
--------------------	-------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Modified) PTO/SB/08A-B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Complete if Known	
	Application Number	09/994,227
	Filing Date	Nov mb r 26, 2001
	First Named Inventor	Alan M. Fogelman
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	407T-899210US
Date Submitted	January 2, 2003	

RECEIVED

JAN 07 2003

TECH CENTER 1600/2900

32	Lundin ET AL. (1986) "Absorption of Intragastrically Administered DDAVP in Conscious Dogs" <i>Life Sciences</i> 38:703-709.
33	Merrifield ET AL. (1995) "Retro and Retroenantio Analogs of Cecropin-Melittin Hybrids" <i>Proc Natl Acad Sci USA</i> 92: 3449-3453.
34	Metzler et al., (1998) <i>J. Biol. Chemistry</i> , 273:(50):33320-33326
35	Metzler et al., (1999) <i>Arterioscler Thromb Vasc Biol.</i> , 1862-1871
36	Navab ET AL. (2002) "Oral Administration of an Apo A-I Mimetic Peptide Synthesized from D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol" <i>Circulation</i> 105: 290-292.
37	Navab et al., (1999) <i>J. Clin. Invest.</i> , 88(6):2039-2046
38	Navab et al., (2000) <i>J. Lipid Research</i> , 41:1481-1494
39	Navab et al., (2001) <i>Arterioscler Thromb Vase Biol.</i> , 21:481-488
40	Navder et al., (1999) <i>J. Lipid Research</i> , 40:983-987
41	O'Brien et al., (1988) <i>Lipids</i> , 23:647-650
42	O'Brien et al., (1993) <i>Lipids</i> , 28:7-12
43	Owens ET AL. (1990) "Apolipoprotein A-I and its Amphipathic Helix Peptide Analogues Inhibit Human Immunodeficiency Virus-Induced Syncytium Formation" <i>J Clin Invest</i> 86: 1142-1150.
44	Panizzutti ET AL. (2001) "A New Strategy to Decrease N-methyl-D-aspartate (NMDA) Receptor Coactivation: Inhibition of D-serine Synthesis by Converting Serine Racemase into an Eliminase" <i>PNAS</i> 98:5294-5299.
45	Pappenheimer ET AL. (1994) "Intestinal Absorption and Excretion of Octapeptides Composed of D Amino Acids" <i>Proc Natl Acad Sci USA</i> 91: 1942-1945.
46	Peng ET AL. (2001) "Effects of L-glutamate, D-aspartate, and Monensin on Glycolytic and Oxidative Glucose Metabolism in Mouse Astrocyte Cultures: Further Evidence that Glutamate Uptake is Metabolically Driven by Oxidative Metabolism" <i>Neurochemistry International</i> 38:437-443.
47	Segrest ET AL. (1992) "The Amphipathic Helix in the Exchangeable Apolipoproteins: A Review of Secondary Structure and Function" <i>J Lipid Research</i> 33:141-166.
48	Sing ET AL. (2000) "Innate Defences Against Viraemia" <i>Rev Med Virol</i> 10:395-403.
49	Srinivas ET AL. (1990) "Antiviral Effects of Apolipoprotein A-I and Its Synthetic Amphipathic Peptide Analogs" <i>Virology</i> 176:48-57.
50	Subbanagounder et al., (1999) <i>Circulation Research</i> , 311-317

Examiner Signature	<i>AM Schmitt</i>	Date Considered	8/14/03
--------------------	-------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.